MedTrace Logo

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

NCT03377556 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2021-06-23

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • ATM Gene Mutation
  • ATR Gene Mutation
  • BARD1 Gene Mutation
  • BRCA1 Gene Mutation
  • BRCA2 Gene Mutation
  • BRIP1 Gene Mutation
  • CHEK1 Gene Mutation
  • CHEK2 Gene Mutation
  • FANCA Gene Mutation
  • FANCC Gene Mutation
  • FANCD2 Gene Mutation
  • FANCF Gene Mutation
  • FANCM Gene Mutation
  • NBN Gene Mutation
  • PALB2 Gene Mutation
  • RAD51 Gene Mutation
  • RAD51B Gene Mutation
  • RAD54L Gene Mutation
  • Recurrent Squamous Cell Lung Carcinoma
  • RPA1 Gene Mutation
  • Stage IV Squamous Cell Lung Carcinoma AJCC v7

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Talazoparib

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Vassiliki Papadimitrakopoulou · SWOG Cancer Research Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-03
Primary Completion
2021-01-10
Completion
2021-04-16
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03377556 on ClinicalTrials.gov